Evidence map›Paper›PMID 25489262›Full record

ArticleCurrent oncology (Toronto, Ont.)2014

BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

F J Huang, W Y Fang, L Ye, X F Zhang, L Y Shen, R L Han, Q Wei, X C Fei, X Chen, W Q Wang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Prevalence ofGland surgery · 2020
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

F J HuangShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
W Y FangShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
L YeShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
X F ZhangShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
L Y ShenShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
R L HanShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
Q WeiDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
X C FeiDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
X ChenDepartment of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
W Q WangShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
S WangShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China. ; Laboratory for Endocrine and Metabolic Diseases of Institute of Health Science, Shanghai JiaoTong University School of Medicine, and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
G NingShanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, and Shanghai e-Institute for Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China. ; Laboratory for Endocrine and Metabolic Diseases of Institute of Health Science, Shanghai JiaoTong University School of Medicine, and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Ruijin Hospital · CNShanghai Institutes for Biological Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated correlations of somatic BRAF V600E mutation and RET/PTC1 rearrangement with recurrent disease in Chinese patients with papillary thyroid carcinoma (ptc).

methodsThis prospective study included 214 patients with ptc histologically confirmed between November 2009 and May 2011 at a single institute.

resultsWe found somatic BRAF V600E mutation in 68.7% and RET/PTC1 rearrangement in 25.7% of the patients. Although BRAF mutation was not significantly associated with clinicopathologic features such as patient sex or age, multicentric disease, thyroid capsule invasion, tumour stage, or nodal metastasis, it was significantly associated with recurrent disease. Multivariate analysis revealed that BRAF mutation and tumour size were independent risk factors associated with recurrent disease, with odds ratios of 9.072 and 2.387 respectively. The area under the receiver operating characteristic curve increased 8.3% when BRAF mutation was added to the traditional prognostic factors, but that effect was statistically nonsignificant (0.663 vs. 0.746, p = 0.124). RET/PTC1 rearrangement and nodal metastasis were significantly associated in all patients (p = 0.042), marginally associated in ptc patients (p = 0.051), but not associated in microptc patients (p = 0.700). RET/PTC1 rearrangement was not significantly associated with recurrent disease.

conclusionsBRAF positivity is an independent predictor of recurrent disease in ptc.

Indexed as

BRAFPapillary thyroid carcinomarecurrenceRET/PTC1

Identifiers

PMID25489262
PMCPMC4257118
OpenAlexW1985090322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.